Document is current
Any future updates will be listed below
-
Authors
Wee, Yinshen
Wang, Junhua
Wilson, Emily C.
Rich, Coulson P.
Rogers, Aaron
Tong, Zongzhong
DeGroot, Evelyn
Gopal, Y. N. Vashisht
Davies, Michael A. https://orcid.org/0000-0002-0977-0912
Ekiz, H. Atakan
Tay, Joshua K. H. https://orcid.org/0009-0004-0626-8662
Stubben, Chris
Boucher, Kenneth M. https://orcid.org/0000-0003-2833-0127
Oviedo, Juan M.
Fairfax, Keke C. https://orcid.org/0000-0002-8382-2960
Williams, Matthew A.
Holmen, Sheri L.
Wolff, Roger K.
Grossmann, Allie H. https://orcid.org/0000-0002-7665-1403
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA230630-01A1)
American Cancer Society (133649RSG1901901CSM)
U.S. Department of Defense (W81XWH2210910)
- License Information
-
More Information
Article History
Received: 4 January 2024
Accepted: 24 July 2024
First Online: 4 August 2024
Competing interests
: M.A.D. has been a consultant to Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, Merck, and ABM Therapeutics, and he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, Pfizer, ABM Therapeutics, and LEAD Pharma. The remaining authors declare no competing interests.
